← boardnext 2026-10
ABOS
Acumen Pharmaceuticalsdistress 6/10 · elevated risk$2.17-2%today-36% from 52w high
Lead: Alzheimer Disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$128M
Runway
1.2 yrs
Shares 1y
+19%
Price & events
+9.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
+0.0%
1W
-10.0%
1M
-18.7%
3M
+9.6%
6M
+29.2%
1Y
-38.7%
2Y
-87.3%
5Y
-89.2%
All
Overview
- Market Cap
- $156.73M
- Enterprise Value
- $121.86M
- Volume
- 25.41K
- 52 Week Range
- $1.23 – $3.37
- Total Shares
- 72.23M
- Float Shares
- 36.96M
- Short %
- 5.54%
- % Held by Insiders
- 6.80%
- % Held by Institutions
- 64.20%
- RVOL
- 0.04x
- Beta
- 0.34
Pipeline stages · 1 programs
sabirnetug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 2 | sabirnetug | Alzheimer Disease | — | active not recruiting |
Catalyst news & presentations · 4
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-16partnershipEBD candidates (sabirnetug-derived & ACU234-based) · Acumen exercises option to license and develop two enhanced brain delivery candidates for Alzheimer's disease under its JCR collaboration.SEC 8-K
- early 2026readoutEBD product · Preclinical data package for EBD productSEC 8-K
- 2025-07-15partnershipStrategic collaboration with JCR for brain delivery productSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+241% upside) · 5 analysts
- 2026-03-26BTIGBuy
- 2026-03-16BTIGBuy
- 2026-01-27BTIGBuy
- 2025-11-18B of A SecuritiesBuy
- 2025-08-25B of A SecuritiesBuy
- 2025-06-17CitigroupBuy
Competitors — Alzheimer Disease
- LLYELI LILLY & Co$1094.4B · D3
- JNJJOHNSON & JOHNSON$617.4B · D0
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ARWRARROWHEAD PHARMACEUTICALS, INC.$12.3B · D3
- LNTHLantheus Holdings, Inc.$6.6B · D0
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- INMBInmune Bio, Inc.$47M · D5
- IGCIGC Pharma, Inc.$27M · D7
- NRSNNeuroSense Therapeutics Ltd.$22M · D5
Recent news
- 2026-07-17Acumen Pharmaceuticals Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock Slips - Special Dividend Alert - dars.gov.et
- 2026-07-17Acumen Pharmaceuticals Inc. Q1 2026 Earnings: Narrowed Loss Beats Expectations, Stock Slips - Return On Equity - dars.gov.et
- 2026-07-15Acumen Pharmaceuticals Presents Enhanced Brain Delivery Program Data and Early Alzheimer?S Disease Insights At Alzheimer?S Association International Conference 2026 - marketscreener.com
- 2026-07-15Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights - Yahoo Finance
- 2026-07-15Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? - Yahoo Finance Singapore
- 2026-07-15Acumen Pharmaceuticals Reports Enhanced Brain Penetration of EBD Antibodies and Patient Experience Findings at AAIC 2026 - Quiver Quantitative
- 2026-07-15All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy - Yahoo Finance
- 2026-07-12Acumen Pharmaceuticals, Inc. promotes presence as Silver Sponsor at Alzheimer association conference in London - Traders Union
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.